Literature DB >> 14745057

Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.

N Attal1, J Rouaud, L Brasseur, M Chauvin, D Bouhassira.   

Abstract

OBJECTIVE: To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
METHOD: The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
RESULTS: Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
CONCLUSIONS: These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745057     DOI: 10.1212/01.wnl.0000103237.62009.77

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks.

Authors:  Angela Mailis; Paul Taenzer
Journal:  Pain Res Manag       Date:  2012 May-Jun       Impact factor: 3.037

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Continuous wound infusion of ropivacaine for the control of pain after thoracolumbar spinal surgery: a randomized clinical trial.

Authors:  Bo Xu; Li Ren; Weifeng Tu; Zenghui Wu; Fuzhi Ai; Dongxu Zhou; Biyun Chen; Xingan Zhang
Journal:  Eur Spine J       Date:  2015-05-03       Impact factor: 3.134

Review 5.  Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy.

Authors:  Ian Carroll
Journal:  Curr Pain Headache Rep       Date:  2007-02

6.  Intravenous Lidocaine for Refractory Chronic Orofacial Pain: Two case reports and a literature review.

Authors:  Abdulaziz Almahrezi; Louise Lamb; Mark A Ware; Yoram Shir; Ibrahim Al-Zakwani
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

7.  Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain.

Authors:  Aldric T Hama; Ann Woodhouse Plum; Jacqueline Sagen
Journal:  Pharmacol Biochem Behav       Date:  2010-08-21       Impact factor: 3.533

8.  Multivariate analysis of chronic pain patients undergoing lidocaine infusions: increasing pain severity and advancing age predict likelihood of clinically meaningful analgesia.

Authors:  Ian Carroll; Raymond Gaeta; Sean Mackey
Journal:  Clin J Pain       Date:  2007-10       Impact factor: 3.442

9.  Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success.

Authors:  Ian R Carroll; Kimberly M Kaplan; Sean C Mackey
Journal:  J Pain Symptom Manage       Date:  2008-01-28       Impact factor: 3.612

Review 10.  Deconstructing the neuropathic pain phenotype to reveal neural mechanisms.

Authors:  Christian A von Hehn; Ralf Baron; Clifford J Woolf
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.